NICE drug guidance change is 'beyond benchmark'Monday 18 October 2010
NICE drug guidance change is 'beyond benchmark'
Dr Ros Altmann, Director-General of Saga, commenting on NICE’s decision to change guidance on availability of drugs to people with early-stage or mild Alzheimer’s said: “The decision by NICE – The National Institute for Health and Clinical Excellence - to change its guidance on drugs which can help people with early-stage or mild Alzheimer’s is a landmark the importance of which is almost beyond benchmark”.
“Although billions of pounds have been put into the NHS in the past decade, stories about patients being denied life-changing drug treatments on account of cost have enraged and outraged. This is particularly true when it comes to the treatment of Alzheimer’s.
“What was not previously taken into account by NICE – The National Institute for Health and Clinical Excellence - was the benefits of treatment to those caring for the patients, as well as the patients themselves, nor the social benefits of a drug which enables a patient to stay in or return to the workforce and home. This was simply wrong.
“To say that we are delighted at this change actually belittles the immensity of the positive impact this change in permitted use of these drugs will have on the lives of suffers and their families.”
For more information please contact the Saga Press Office on 01303 771529.
Share this page
The Saga Group Communications Team only deal with enquiries from the media.
If you're not a journalist, visit our contact us page for a full list of telephone numbers.